🕒 Created

Boston Scientific Corporation lowered 2026 revenue growth expectations due to market pressure in the U.S.

Boston Scientific Corporation lowered its 2026 expectations, now projecting organic revenue growth of 5% to 6% and adjusted earnings per share of $3.28 to $3.32. The company faces pressure from a sharp slowdown in the U.S. market for WATCHMAN and greater competitive share losses in the United States for its Electrophysiology business.

Show the rest of this summary

Management expects these headwinds to continue into 2027, with revenue growth potentially remaining below the weighted average market growth rate. To offset these challenges, the company is pursuing a restructuring program aimed at $500 million in annual run-rate savings by the end of 2029. These savings will focus on supply-chain optimization, functional changes, and organizational restructuring. Growth is expected to pick up in 2028 as new catalysts take effect, including seven new launches with a total addressable market exceeding $25 billion. The pending Penumbra acquisition also serves as a long-term growth driver. Over the past 12 months, Boston Scientific Corporation shares have declined by 55.8%.

Sources

Paywall and unreadable sources